Press Room

2021 AIChE Annual meeting

Start
Monday, November 15, 2021 - 00:00
End
Monday, November 15, 2021 - 00:00
Location: Online
Hovione present at AICHE with scientific presentations

Meet Hovione Scientists virtually at 2021 AIChE Annual Meeting and find their exciting presentations on the latest research and innovations:

 

Date: November 15th, 2021

Title: Enabling Continuous Antisolvent Crystallization Using Hollow Fibre Membranes
Author: António Henriques, Rui César

Session: Virtual Crystallization and Evaporation Talks

Date: November 16th, 2021

Title: Process Safety Evaluation and Scale-up Resorting to Mechanistic Modelling for Exothermic and Gas Release Reactions
Author: Filipe Ataíde

Session: Predictive Scale-Up/Scale-Down for Production of Pharmaceuticals and Biopharmaceuticals

Title: Reaction Kinetic Modelling Coupled with Process Safety Calorimetry for Effective Scale-up of an Exothermic Reaction
Author: Filipe Ataíde

Session: Predictive Scale-Up/Scale-Down for Production of Pharmaceuticals and Biopharmaceuticals

Date: November 18th, 2021

Title: Spray-Dried Amorphous Solid Dispersions for Nasal Delivery: Development, Characterization and Performance
Author: Patrícia Henriques

Session: Advances in Drug Discovery and Drug Delivery

 

Schedule a meeting with our experts

We will work together to ensure successful scale-up even with the tightest development timelines

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026